Welcome to our dedicated page for Apnimed SEC filings (Ticker: APMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Apnimed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Apnimed's regulatory disclosures and financial reporting.
Apnimed, Inc. (APMD) reported the initial equity holdings of director Paul R. Fonteyne in an initial statement of beneficial ownership. The filing lists two stock option awards over Class A Common Stock with specified exercise prices, share amounts, vesting schedules, and expiration dates.
One option allows purchase of 51,890 shares at $4.0000 per share, expiring on September 18, 2033, vesting 25% after twelve months of continuous service from September 18, 2023, with the remainder vesting in substantially equal quarterly installments over 36 months. A second option covers 44,477 shares at $8.1500 per share, expiring on July 7, 2036, with 25% vesting after twelve months of continuous service from July 7, 2026 and the remainder vesting in substantially equal quarterly installments over 36 months.
Apnimed, Inc. (APMD) reports that director Gary Sender holds two stock option awards. One option to acquire 51,890 shares of Class A Common Stock has an exercise price of $9.50 and expires on December 12, 2034. Another option to acquire 44,477 shares has an exercise price of $8.15 and expires on July 7, 2036. For each option, 25% of the shares vest after twelve months of continuous service from the specified start date, with the remaining shares vesting in substantially equal quarterly installments over the following 36 months, subject to continued service.
Apnimed, Inc. (APMD) reported that William A. Jones Jr. filed an initial statement of beneficial ownership on Form 3 in his capacity as a director of the company. The filing lists no reportable transactions or derivative positions and references an Exhibit 24 Power of Attorney.
Apnimed, Inc. (symbol APMD) reported that Chris Dimitropoulos is a director and filed an initial statement of beneficial ownership on Form 3. The filing lists no reportable holdings or transactions in Apnimed securities at this time and references an Exhibit 24 Power of Attorney.
Apnimed, Inc. (APMD) reported the initial beneficial ownership of its Chief Executive Officer, Kevin Robert Lind, in a Form 3. He holds stock options giving the right to purchase Class A Common Stock at exercise prices of $9.50 and $8.15, expiring in 2035 and 2036, respectively. These options cover 74,128 and 1,186,278 underlying shares and vest over time based on his continuous service, with 25% vesting after 12 months from the stated start dates and the remainder vesting in installments over the following 36 months.
Apnimed, Inc. (APMD) director Lawrence G. Miller filed an initial Form 3 reporting his existing equity interests. Indirect holdings include 10,845 shares of Series A Preferred Stock and multiple blocks of Class A Common Stock held through several irrevocable family trusts, for which he disclaims beneficial ownership except to the extent of any pecuniary interest. The filing also lists several stock options to buy Class A Common Stock, including options over 688,042 shares at an exercise price of $1.00 per share expiring in 2029, with other options at higher exercise prices and later expirations. The Series A Preferred Stock is convertible into Class A Common Stock on a one-for-one basis and will convert immediately prior to the closing of an initial public offering without additional consideration.